Sweden’s Meda spurns Mylan approach

[at Financial Times] – Meda, the Swedish drugmaker, rejected a takeover approach by US rival Mylan on Friday, potentially scuppering a deal that would have created a $23bn-plus pharmaceuticals business. The rejection came hours … more

View todays social media effects on MYL

View the latest stocks trending across Twitter. Click to view dashboard

See who Mylan is hiring next, click here to view